18-Sept-2026 11:53:27

HALEOSLABS : USFDA INSPECTION OF SUBSIDIARY CONCLUDES WITH ZERO OBSERVATIONS

• United States Food and Drug Administration (USFDA) conducted an inspection of Mahi Drugs Private Limited, a material subsidiary of the company. • The inspection was held at the API manufacturing facility in Anakapalli, Andhra Pradesh. • The facility was inspected from September 15, 2026 to September 18, 2026. • The inspection concluded successfully with zero Form 483 observations. • This mirrors the outcome of the previous USFDA inspection conducted in January 2025.

Haleos Labs Ltd

← Back to feed